Arcutis Biotherapeutics (ARQT) EBT Margin (2022 - 2026)

Arcutis Biotherapeutics' EBT Margin history runs 5 years deep, the most recent figure standing at 10.63% for Q1 2026.

• In Q1 2026, EBT Margin rose 2819.0% year-over-year to 10.63%; the TTM figure through Mar 2026 stood at 0.33% (up 6150.0% YoY), while the FY2025 annual figure was 3.98%, up 7972.0% from the prior year.
• EBT Margin for Q1 2026 stood at 10.63%, down from 13.8% in the prior quarter.
• The five-year high for EBT Margin was 13.8% in Q4 2025, with the low at 14856.41% in Q3 2022.
• The 5-year median for EBT Margin is 109.53% (2023), against an average of 1493.65%.
• The sharpest annual moves came in 2023 and 2024: EBT Margin soared 1474688 bps in 2023, then jumped 1672 bps in 2024.
• Arcutis Biotherapeutics' EBT Margin stood at 2432.25% in 2022, then surged by 94 bps to 150.77% in 2023, then jumped by 90 bps to 15.09% in 2024, then soared by 191 bps to 13.8% in 2025, then slumped by 177 bps to 10.63% in 2026.
• Business Quant data shows ARQT's EBT Margin at 10.63% in Q1 2026, 13.8% in Q4 2025, and 7.55% in Q3 2025.